Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.

“We are asked with some frequency why store these stem cells available only at birth.  On our web site at www.corcell.com is a list of more than 70 diseases that are already treated by these stem cells, including acute and chronic leukemia’s, severe aplastic anemia, Hodgkin’s Disease, a number of inherited metabolic diseases and immune system disorders and malignancies including Ewing Sarcoma and Sickle Cell Disease,” said Matthew Schissler, co-founder and CEO.  ”Once in a while, it is my duty and obligation to step away from the day-to-day and reflect on the larger scope of work in the umbilical cord blood stem cell arena.  In doing so, I recognize that our loyal shareholders may not be privy to all of the data we receive, involving the outstanding studies with these cells.  It is my hope that a simple statement such as this, can direct our shareholders to the resources publicly available.”

“What is truly exciting is that the National Institutes of Health at www.clinicaltrials.gov now lists clinical trials ongoing at such prestigious research institutions as Duke University and Memorial Sloan-Kettering Cancer Center to understand the possible usage of stem cell infusions for the treatment of intractable diseases, including Type I diabetes in children, cerebral palsy in children, chronic spinal cord injuries, lymphoma and other blood borne cancers,” Mr. Schissler said.

“Also, there is research ongoing elsewhere in the world to use umbilical cord blood stem cells to combat Alzheimer’s, cardiac disease, lupus, multiple sclerosis, muscular dystrophy, Parkinson’s Disease, rheumatoid arthritis and stroke.  This truly is an excellent time to be involved in this sector as we work toward our goal of becoming the most significant stem cell company in the world,” said Mr. Schissler.

Existing methods to produce a stem cell concentrate therapy are time consuming, labour intensive, and require complex logistical considerations. The BMAC System helps in safe and rapid preparation of cell concentrate from bone marrow. The process takes only about 15 minutes and can be conducted in the point of care setting.

The system is currently being used clinically in many developed countries like US and Europe for various medical disciplines. These applications range from fractures, non-unions, osteonecrosis, cartilage repair applications and critical limb ischemia (CLI). The system will soon be applied for cardio vascular regeneration.

LifeCell has implemented this technology for an ongoing Indian CLI study which is being led by Dr. K. S. Vijayragavan at Department of Vascular Surgery, SRMC. As per the data available on the interim study conduted on 30 patients after a 12 week followup major amputations were seen only in 4 patients and 6 of them went for minor amputation. The patients’s also reported significant reduction in their pain perception and considerable improvement in quality of life. The study also emphasised the fact that the BMAC process is safe and the Intra-arterial infusion does not cause any adverse reaction.

Talking on the association with Harvest Technologies, Mr. Mayur Abhaya, Executive Director, LifeCell International says, “We are excited to partner with Harvest Technologies to bring-in international standards to India. LifeCell International is today India’s only comprehensive stem cells solutions provider as we offer a complete spectrum of services and with this association we intend to accelerate the availability of advanced stem cell therapy in India.

According to Scott Shea, Managing Director, Harvests Technologies GmbH, “The Autologous regenerative cells from bone marrow offer profound potential for therapies. Harvest has conducted about 30,000 clinical procedures for various applications, the highest number of procedures in the world, using the BMAC System. Our novel technology now makes it possible to harvest the regenerative cells safely and rapidly in order to develop new therapies for heretofore incurable diseases.”
“We are delighted to be associated with LifeCell, an undisputed market leader in stem cell technology space and extend our services in India.  LifeCell has a well established network with hospitals and clinical institutions across India and we would leverage their strength to rapidly deploy our service across the country and provide HOPE in addressing unmet medical challenges by offering cellular therapeutic options.”

Commenting on the interim report presented on the studies conducted for CLI in India using the BMAC technology, Mr. Mayur added, “Through our clinical research, we have identified that the transplantation of autologous Bone Marrow Aspirate Concentrate (BMAC) into critically ischemic leg can increase blood flow and support in healing the wounds quickly. It also helps in reducing pain and avoiding leg amputation of otherwise incurable patients. This is also validated by the outcome of the CLI study which showed that 86.6% of patients could avoid amputation.”

Diagnosed at birth with aplastic anemia, Titus Chang was saved by a cord blood transplant from his newborn brother. For info about cord blood, go to cordblood.com and request a free info kit. … cordblood cord blood stem cell cells children kids baby babies pregnant pregnancy prenatal health treatment cure

Your baby is about to change your life. Thanks to Cryo-Cell, one day she may save it. … cordblood umbilical cord pregnant bump stem cell stemcell

This short video describes the collection of cord blood stem cells and the advantages of Cord Blood Registry’s collection kits. This process happens after the birth of the child and does not affect the health of the mother or baby. For a free information kit, click here www.cordblood.com … Cord blood Stem Cells Pregnancy Baby Diabetes Leukemia Cancer Sickle Cell Anemia Heart Disease Health Medicine